Raja Mudad, M.D., FACPThoracic Medical Oncologist

Raja Mudad, M.D., FACP - Thoracic Medical Oncologist

Dr. Mudad is a medical oncologist who specializes in lung cancer. He received his B.S. in Biology with high distinction in 1985 and his M.D. with distinction in 1989 from the American University of Beirut.

He completed an internship and residency in 1992 in Internal Medicine at Duke University Medical Center in Durham, North Carolina. Dr. Mudad continued at Duke as a fellow in Hematology and Medical Oncology and completed his fellowship in 1995.

Dr. Mudad joined the Tulane University faculty where he became an Associate Professor of Medicine. In 1996 Dr. Mudad was appointed Chief of the Section of Hematology/Oncology at the Veterans Administration Medical Center in New Orleans and was also the Associate Chief, Section of Hematology and Medical Oncology at Tulane Medical School and Director of Hematology/Oncology Fellowship Training between 2001-2006.

Dr Mudad's primary interest and research is in the field of solid tumor oncology and specifically lung cancer. He has conducted several clinical trials in lung and head & neck cancer. He was the director of the Lung Cancer Program at the Memorial Healthcare system in Hollywood, FL from 2006 until 2012, and later joined the University of Miami. He has served as the associate director of the Hematology/Oncology fellowship program and was active in clinical trials focused on lung cancer. Dr. Mudad is the recipient of several local, regional and national awards.

Professional Appointments

  • Florida Precision Oncology (a division of 21st century Oncology), Medical Oncologist, Aventura, FL June 2019-
  • Medical Director, Chemotherapy Treatment Units, Sylvester Comprehensive Cancer Center, December 2016-2019
  • Co-Chief Medical Informatics Officer (CMIO), Sylvester Comprehensive Cancer Center, October 2015-2019
  • Associate Director, Hematology/Oncology Fellowship Program, University of Miami Health System, Sylvester Comprehensive Cancer Center, 2018-2019
  • Physician Champion, ICHOM (International Consortium for Health Outcomes Measurement) Lung cancer working group for Sylvester Comprehensive Cancer Center, October 2015-2019
  • Physician representative at the Alliance of Dedicated Cancer Centers (ADCC) for Sylvester Comprehensive Cancer Center, 2015- 2019
  • Physician Lead, BEACON (electronic chemotherapy ordering system), Sylvester Comprehensive Cancer Center, November 2013-2019
  • Associate Professor of Medicine (Pending), University of Miami Health System, Sylvester Comprehensive Cancer Center, 2019
  • Assistant Professor of Medicine, University of Miami Health System, Sylvester Comprehensive Cancer Center, November 2013-2019
  • Cancer Cure, PA-Raja Mudad, M.D., Private Practice, Hollywood, FL, November 2012-October 2013.
  • Associate Director, Memorial Cancer Institute, Hollywood, FL., August 2008-September 2012
  • Chairman, Tumor Board, Memorial Regional Hospital, Hollywood, FL., July 2006-2012
  • Vice-chair, Hematology/Oncology Department, Memorial Regional Hospital, Hollywood, FL., May 2012-November 2012
  • Co- Director, Thoracic Oncology Program, Memorial Cancer Institute, Hollywood, FL., July 2011-September 20, 2012.
  • Director, Thoracic Oncology Program, Memorial Cancer Institute, Hollywood, FL., July 1, 2006- July 2011
  • Associate Section Chief, Hematology/Oncology Section, Tulane University School of Medicine, August 2001- June 2006.
  • Chief, Hematology/Oncology Section, New Orleans VA Medical Center, June 1996- June 2006.
  • Director, Hematology/Oncology fellowship program, July 2001- June 2006.
  • Acting Chief, Hematology/Oncology Section, Tulane University School of Medicine, July 2001-August 2001.
  • Associate Chief, Hematology/Oncology Section, Tulane University School of Medicine, November 1, 2000-June 2001.
  • Associate Professor of Medicine, Hematology/Medical Oncology, Tulane University School of Medicine, July 2001- May 2006.
  • Assistant Professor of Medicine, Hematology/Medical Oncology, Tulane University School of Medicine, June 1996-June 2001.
  • Associate Director, Hematology/Oncology fellowship program, July 1996-June 2001.
  • Associate in Medicine, Hematology/Medical Oncology, Tulane University School of Medicine, July 1995-May 1996.

Education & Training

Fellowship:
Hematology/Oncology, July 1992-June 1995
Duke University Medical Center
Durham, NC 27710
Residency:
Internal Medicine, July 1990-June 1992
Duke University Medical Center
Durham, NC 27710
Internship:
Internal Medicine, July 1989-June 1990
Duke University Medical Center
Durham, NC 27710
Medical School:
Doctor of Medicine, July 1985-June 1989
Distinction
American University of Beirut
Beirut, Lebanon
College:
Bachelor of Science, Biology, 1982-1985
High distinction
American University of Beirut
Beirut, Lebanon

Specialty Board Status

  • Board Certified in Internal Medicine, (ABIM) September 1992-2002
  • Board Certified in Medical Oncology, (ABIM) November 1995-2025
  • Board Certified in Hematology, (ABIM) November 1996-2016

Medical Licensure

  • Florida, 2006-present
  • Louisiana, 1995-2009
  • North Carolina 1989-1995
  • ECFMG Certificate, 1989
  • Flex, 1990

Clinical Activities

  • Clinical responsibilities: 60%

    Staffing the lung cancer clinic with the fellows, Jackson Memorial Hospital

    Weekly one-day clinic at Sylvester Hollywood Satellite, Hollywood, FL (Lung cancer, Head and Neck Cancer)

    Two days of clinic at Sylvester Cancer Center main campus (Lung cancer, Head and Neck Cancer)

  • Administrative/Research/Education: 40%
    • Various didactic lectures throughout the institution
    • Fellowship work
    • Manuscript preparation
    • PI on multiple national studies
    • Research paperwork completion/meetings/site visits
    • Directorship work for Beacon, Chemotherapy treatment unit and fellowship (40% salary support)

Honors & Awards

  • Compassionate Doctor Recognition Award, Vitals.com, 2011
  • Patient’s choice award, Vitals.com, 2011
  • On-time physician award, Vitals.com, 2009
    Read more: www.vitals.com
  • Physician of the year award, Memorial Cancer Institute, 2011
  • Leadership Recognition Award, Inpatient Oncology Unit, Memorial Regional Hospital, Hollywood, FL, May 2010
  • American Cancer Society spirit award recipient, 2004.
  • Thorpe Ray Outstanding Faculty Teacher Award, Tulane University School of Medicine, June 2003
  • Outstanding teaching award, Tulane University School of Medicine, June 1998
  • Outstanding teaching award, Tulane University School of Medicine, June 1997
  • Member of the Musser-Burch Honorary Society, Tulane University School of Medicine, January 1996
  • Distinction, MD degree, American University of Beirut, June 1989
  • High Distinction, BS degree, American University of Beirut, June 1985

Membership in Professional Organizations

  • American College of Physicians, Member 1993-1998, Fellow 1998-present
  • American Society of Hematology, Associate Member 1993, Member 1996
  • American Society of Clinical Oncology, Member 1997
  • IASLC member, 2012
  • ECOG-ARIN, Member 2016
  • Southwest Oncology Group, Member 1995-2006
  • Louisiana Oncology Society, 1996-1998

Membership in Committees

  • Chair, Beacon Governance Committee
  • Chair, Clinical Advisory Committee for Sylvester Comprehensive Cancer Center
  • Chair, search committee Thoracic and Head and neck recruits (successfully hired 2 oncologists)
  • Member, Hematology/Oncology fellowship committee
  • Member, CTU council
  • Member, Search committee for Breast Cancer leader
  • Member Fellowship Committee, University of Miami Hematology/Oncology fellowship program, January 2014-
  • Chairman, Tumor Board Conference, Memorial Regional Hospital, Hollywood, FL, 2006-2012
  • Member, Cancer Committee, Memorial Regional Hospital, Hollywood, FL, 2006-2012
  • Chairman, Cancer Committee, New Orleans VA Medical Center, 1996- 2006
  • Member, Tulane Cancer Center steering committee, November 2000- May 2006
  • Member, Hematology/Oncology Fellowship committee, Tulane University School of Medicine, July 1996- May 2006
  • Member, Housestaff Hearing Committee, Residency Training Program, Tulane University School of Medicine, August 1996- May 2006
  • Member of the Cancer Care Subgroup Committee, Department of Veterans Affairs, VISN 16, 1998
  • Member, Ethics Committee, Tulane University Hospitals and Clinics, July 1999-June 2001.
  • Member, Performance Improvement Council, Tulane University Hospitals and Clinics, July 2000-June 2001.
  • Member, Lung committee and GU committee, Southwest Oncology Group, 1996-2006.

Selected Invited Lectures and Courses

  • “Lung cancer review”, 3 lectures, Costa Rica, November 2018.
  • “ASCO 2017 Update” Webcast for Brasil, University of Miami Global Oncology program, November 20, 2017
  • “The status of immunotherapy in Lung Cancer”, 3rd Jornada Instituto de Oncologia Dr. Heriberto Pieter, Santo Domingo, DR, November 8, 2017
    • Presenter, “adjuvant Targeted Therapy in NSCLC” IASLC Latin American Conference, Panama City, Panama, August 2016
    • Abstract reviewer, IASLC Latin America meeting, Panama, August 2016.
  • “Living Room” presentation, “The patient as a Unique Individual”. Bonnie Addario Lung Cancer Foundation, San Francisco, CA, May 17, 2016.
  • Oncology Grand Rounds, U.M Hematology/Oncology section, “Is personalized therapy for squamous cell lung cancer on the horizon?” July 8, 2015.
  • Oral Presentation, IASLC/ESMO First International Lung Cancer conference, Geneva, Switzerland, March 2008.
  • Invited lecturer, “Targeted Cancer Therapy”, San Jose, Costa Rica, May 2003
  • Invited lecturer, “Supportive care”, “Flow Cytometry”, “Lung Cancer”, Tegucigalpa, Honduras, April 2003.
  • “Results of first Tulane Cancer Center study RM 98-1” Tulane Cancer center seminar series, January 31, 2002.
  • “Complementary and Alternative Cancer Therapy: Can the Shark beat the Crab?” Medicine Grand Rounds, Tulane Medical School, June 13, 2001.
  • Invited lecturer, Guatemalan Society of ENT surgery, “Role of chemotherapy in Head and Neck Cancer”, “Role of chemotherapy in organ preservation”, Guatemala City, Guatemala, March 7-11, 2001.
  • Invited faculty, Journal Club, Thibodaux, LA “Lung Cancer”, December 2000.
  • Invited lecturer, “Today’s options in Lung Cancer”, Tulane Cancer Center research seminar, July 2000.
  • Invited lecturer, “Today’s options in Lung Cancer for the primary care physician” at the Family Practice Update, Tulane University School of Medicine, Sheraton Hotel, New Orleans LA, May 2000
  • Director and moderator, Tulane Cancer Center Oncology Update 1999, “An update for the primary care physician”, April 30-May 2 1999, New Orleans, LA
  • “An update on the treatment of lung cancer”, Tulane Cancer Center Oncology Update 1999, May 1999, New Orleans, LA
  • “Lung Cancer” lecture for primary care physicians, Tulane University, March 1998
  • “The role of Chemotherapy in Hormone-Refractory Prostate Cancer”, Tulane Cancer Center Oncology Update, October 4, 1997
  • Director and moderator, Tulane Cancer Center Oncology Update, “An update on Prostate and Lung Cancer”, October 4-5, 1997, New Orleans, LA

Community Activities

  • Leader, Lung Cancer support group, Hollywood, FL (November 2012-present)
  • “Cancer and the LGBT community”, lecture at the Gay and Lesbian community center, Fort Lauderdale, FL (February 2009)
  • Smoking prevention lectures for school children (8th graders) in the south Florida community (2006, 2007, 2008)
  • Lung cancer support group, Gilda’s club, Fort Lauderdale, FL (2006-2013)

Completed Projects

  • “Cancer patients’ attitudes towards medical marijuana” 2015 ($5000 grant, SCCC)

Research Experience

CLINICAL

  • SWOG Young Investigator Training course, Seattle/San Antonio, March 2000
  • PI for multiple clinical trials in Lung Cancer, Sylvester Comprehensive Cancer Center, 2014-present
  • PI for multiple clinical trials in NSCLC and Head and Neck cancer at the Memorial Cancer Institute, 2006-2012.

Clinical trials

  • PI: Afatinib expanded access program for patients with EGFR mutated NSCLC: Sponsor BI (enrolled 10 patients) completed 2013
  • PI: The Alchemist Lung Cancer Trials (Three trials), Sylvester Comprehensive Cancer Center, 2015
  • PI: Adaptimmune Lung Cancer Trials, Sylvester Comprehensive Cancer Center, 2015
  • PI: AURA 3 trial (Astra Zeneca sponsor) AZD9291 in T790M positive NSCLC patients, Sylvester Comprehensive Cancer Center, 2015 Completed

Investigator-initiated protocols

  • Co-investigator in clinical protocol “A phase II study for treatment with I-131 MIBG in patients with metastatic carcinoid”. Principal investigator Jon P. Gockerman, M.D. Duke University Medical Center, Durham, NC, 1993.
  • Principal investigator in clinical protocol “A pilot/phase II trial of high dose Tamoxifen (TAM) and Vincristine, Adriamycin, Dexamethasone (VAD) in patients with refractory multiple myeloma”. Tulane University Medical Center, New Orleans, LA, 1995. (Closed)
  • Principal investigator in clinical protocol “A phase II study of Taxol in patients with Kaposi’s sarcoma”. Tulane University Medical Center, New Orleans, LA, 1996-1999. (closed)
  • Co- investigator in clinical protocol “Blood sampling in clinical cancer research” for evaluation of BCL2 expression in patients with Lymphoma. Principal investigator l: Melanie Ehrlich, Ph.D., Tulane University Medical Center, New Orleans, LA, 1996.
  • Principal investigator in clinical protocol “A phase II study for the treatment of patients with hormone refractory metastatic prostate carcinoma with Mitoxantrone, Prednisone and Pamidronate” Tulane University Medical Center, New Orleans, LA, 1997-1999. (Closed)
  • Principal investigator in clinical protocol “Combined modality therapy for locally advanced non-small cell lung cancer with weekly Cisplatin, Docetaxel and Radiation: a phase I/II study” Tulane University Medical Center, New Orleans, LA, 1998. (Completed)
  • Principal investigator in clinical protocol “A phase II trial of adjuvant chemotherapy
  • for high risk transitional cell carcinoma of the urothelium” Tulane University Medical Center, New Orleans, LA, 2001 (closed)
  • Study Chair, SWOG Protocol S0022: “ Phase II Trial of concurrent Cisplatin/Docetaxel and radiotherapy followed by consolidation Docetaxel in stage IIIB NSCLC”, activated March 2001, completed December 2002.
  • Senior Principal investigator in clinical protocol “Evaluation of Arsenic Trioxide in Combination with 5-Fluorouracil in Gastrointestinal Tract Tumors” PI: Bilal Ansari, M.D., Fellow 2003 (closed)
  • Co-chair, SWOG Protocol S0310: “A Phase II study of GVAX in bronchioalveolar carcinoma”, closed December 2004.

BASIC

  • Expression cloning of JMH blood group antigen through screening of a human cDNA library, characterization of various monoclonal and human antibodies to JMH, purification of JMH protein from red cells, investigation of JMH role in hematopoiesis.  Director, Marilyn J. Telen, MD. Duke University Medical Center, Durham, NC. September 1993-June 1995.
  • The Role of p-38 Mitogen Activated Protein Kinase in radiation induced esophagitis and pneumonitis in mice. PI: Tyler Curiel, M.D. (proof of concept experiment prior to development of human trial). June 2002- May 2006.

GRANTS

  • Bristol-Myers Oncology Division, grant support for protocol: “A phase II study of Taxol in patients with Kaposi’s sarcoma”, $28,000, January 1997-January 1999, Principal Investigator. (closed)
  • Immunex, grant support for protocol: “A phase II study for the treatment of patients with hormone refractory metastatic prostate carcinoma with Mitoxantrone, Prednisone and Pamidronate”, $25,000, May 1997-November 1999, Principal Investigator. (closed)
  • Rhone-Poulenc Rorer, grant support for protocol: “Combined modality therapy for locally advanced non-small cell lung cancer with weekly Cisplatin, Docetaxel and Radiation: a phase I/II study”, $110,000.00, May 1998-completion of study, Principal investigator. (Completed)
  • Amgen, grant support for protocol:“RM-002:A Phase II Trial of adjuvant chemotherapy for high-risk transitional cell carcinoma of the urothelium” $60,000.00, Principal investigator (closed)
  • Bristol-Myers Oncology division:“RM-002: A Phase II Trial of adjuvant chemotherapy for high-risk transitional cell carcinoma of the urothelium” $90,000.00, Principal investigator (closed)
  • CTI pharmaceuticals “BA 002: Arsenic Trioxide and 5FU in refractory GI malignancies” $97,125.00, Principal investigator (closed)

Publications

Book Chapters

  • Mudad R, Telen MJ: Autoimmune Hemolytic Anemia. In: Conn's Current Therapy, Rakel RE ed. W.B. Saunders Co. Philadelphia, PA., pp 340-344, 1996.
  • Mudad R: Lung Cancer, In: Oklahoma Notes, Biostat publishing Co., Oxnard, California, 2001.
  • Lung Cancer: Standards of Care. 1st Ed. McGraw-Hill Editorial. 2018 (Contributing author)

Book Reviews

  • Mudad R. Review of: Scientific Writing: Easy When You Know How. Peat, Jennifer; Elliott, Elizabeth; Baur, Louise; Keena, Victoria. Doody's Review Service (on-line). Available: www.doody.com. (Accessed 11/02).

Editorial Activities

  • Journal: Current Pulmonology Reports, Section editor for Lung Cancer (2016-2018)
  • Created list of topics and assigned papers to various authors. Edited final manuscripts and prepared them for publication. Sample articles below:
  • NSCLC: State of the Art Diagnosis, Treatment, and Outcomes - Gerard Chaaya, Ramsy Abdelghani, Fayez Kheir, Takefumi Komiya, Nancy Vander Velde
  • Making Sense of Immunotherapy in Lung Cancer: What the Pulmonologist Needs to Know? Edgardo S. Santos Moises Harari Turquie, Lilibeth Castillero, Luis E. Raez, Christian Rolfo
  • Consensus on Molecular Testing in Lung Cancer - Parth Shah, Jacob Sands
  • Treatment of Advanced Non-Small Cell Lung Cancer in the Era of Targeted Therapy Mohamad Masri, Martine McManus, Raja Mudad

Abstracts/Posters

  • Vredenburgh J, Mudad R, Paulson E, Ross M, Meisenberg B, Hussein A et al: Hepatic, splenic and renal candidiasis following high dose chemotherapy (HDC) and autologous bone marrow support. Proc Am Soc Clin Oncol 12:456 (abstract1583),1993.
  • Mudad R, Rao N, Angelisova P, Horejsi V, Telen MJ: Evidence that CDw108 membrane protein bears the JMH blood group antigen. Blood 84 (10), suppl 1:237a    (abstract 934), 1994. Presented, ASH meeting, Nashville TN, December 1994.
  • Mudad R, Levesque M, Vredenburgh J, Telen MJ: Serum level of soluble CD44
  • (sCD44) in various malignancies. Proc Am Soc Clin Oncol 14:83 (abstract 36),
  • 1995.
  • Issitt P, Combs M, Mudad R, Telen MJ: An anti-JMH causing in vivo red cell destruction. American Association of Blood Banks meeting, New Orleans, LA,1995, (Poster presentation).
  • Mudad RA, Saux JE, Lastrapes AJ, Zaydan MAA: Evaluation of knowledge regarding
  • cancer pain management among physicians in training: A pilot study. The 4th Annual VA Oncology Symposium, Washington, DC, October 1999, (Poster presentation).
  • Mudad RA, Cohen JE, Zakris E, Rozans M, Wynn R, Mai PL: Endobronchial
  • brachytherapy in the management of obstructive lesions in Non-small cell lung carcinoma. The 4th Annual VA Oncology Symposium, Washington, DC, October 1999, (Poster presentation).
  • Chandramohan S, Rice J, Mudad R: Assessment of fatigue among veterans receiving
  • chemotherapy for cancer. Proceedings of the American Society of Clinical Oncology, (19): 636a, 2000 (abstract 2511).
  • Mudad R, Zakris EL: Concomitant Docetaxel, Cisplatin and radiation (XRT) in the treatment of locally advanced non-small cell lung cancer (NSCLC): A phase I study. Proceedings of the American Society of Clinical Oncology, (19): 545a, 2000 (abstract 2146A).
  • Mudad R, Zakris EL: Maximal tolerated dose (MTD) of weekly Docetaxel with Cisplatin and radiation (XRT) in locally advanced non-small cell lung cancer (NSCLC): A phase I study. Proceedings of the twelfth international congress on anti-cancer treatment, Feb 4, 2002, p119, Paris, France (oral presentation).
  • Arias G, Bahan K, Mudad R: Why Do Veterans Not Receive Concomitant Chemoradiation For Locally Advanced NSCLC? A Retrospective Review. The 7th Annual National VA Oncology Symposium, Alexandria, VA October 2-4, 2002 (Poster presentation).
  • Mudad R, Zakris E, Kovitz K, Nedzi L. Non-malignant pericardial effusion as a long-term complication of combined modality therapy in non-small cell lung cancer (NSCLC). Lung Cancer Vol. 49, Suppl. 2 (2005), pS173, Abstract P220. 11th World Conference on Lung Cancer, Barcelona, Spain July 2005 (Poster presentation, outstanding poster)
  • Higgins K, Gilbert J, Mudad R, Friedlander B, Fazekas M, Pou A, Wisdom G, Hanner S, Zakris E, Nedzi L: Variables associated with missed days of radiation in patients undergoing curative therapy for squamous cell carcinoma of the Head and Neck
  • Poster presentation at ASTRO 2005, Denver, Colorado.
  1. Higgins, J. Gilbert, R. Mudad, P. Friedlander, M. Fazekus, A. Pou, G. Wisdom, S. Hanner, E. Zakris and L. Nedzi: Socioeconomic Study of Mortality in Patients Undergoing Curative Radiation Therapy (RT) for Squamous Cell Carcinoma (SCC) of the Head and Neck. Poster presentation at ESTRO 2005, Paris, France.
  • Nedzi L, Walsh J. W, Weiner R, Payne B. R, Zakris E, Sanford R, Pearman T, Rosel P, Mudad R, Hall A, Weber J: Localized Therapy for Limited Metastatic Disease to the Brain: A Phase II Study of Surgery, Stereotactic Radiosurgery(SRS) and Stereotactic Radiotherapy(SRT) in Favorable Patients. Poster Presentation at ISRS 2005, Brussels, Belgium.
  • Mudad R, Block M, Forsyth P, Frankel C, Annesty D, Hussein A: Feasibility of lung cancer screening in a South Florida community. Poster Presentation at the 1st European Lung cancer conference, Geneva, Switzerland, April 2008 (abstract # 99) (Oral presentation)
  • Nedzi L, Walsh J, Weiner R, Zakris E, Sanford R, Pearman T, Mudad R, Timmerman, R, Mickey, B, Abdulrahman,R, Madden, C, Whitworth, A and Crockett, J: Localized Therapy for Limited Metastatic Disease to the Brain: A Phase II Study of Surgery, Stereotactic Radiosurgery and Stereotactic Radiotherapy in Favorable Patients: Final results.Poster Presentation at ISRS 2011
  • L.E. Raez, C. Sareli, Raja Mudad, F. Tarrazzi, Evelio Velis, S. Sundararaman, M. Block: Exploring Disparities in Health Care Outcomes in minority populations with Small (SCLC) and Non-small cell lung cancers (NSCLC). Abstract presentation (Dr. Raez) at the World Lung Cancer Conference, Sydney, Australia, October 2013. (Poster)
  • Raja Mudad, Manish B Patel, Sandra Margunato-Debay, Lincy S. Lal, David Garofalo: Comparative effectiveness and safety of nab-paclitaxel plus carboplatin (nab-P/C) versus gemcitabine plus carboplatin (gem/C) in first-line treatment of advanced squamous cell (SCC) non-small cell lung cancer (NSCLC) in a U.S. community oncology setting. JNCCN Volume 14 Number 5.5, p 20-21 NCCN Annual Conference, March 2016 (Poster)
  • Raja Mudad, Bahar Laderian, Madeline Krause: Medical Marijuana and Lung cancer: Patients' knowledge and attitude towards its use. IASLC WCLC 2016 - IASLC 17th World Conference on Lung Cancer, Vienna Austria, Abstract 3994 December 2016 (Poster)
  • Wungki Park, Raja Mudad: Central nervous system (CNS) responses to Osimertinib in brain metastases from lung cancer (NSCLC) with T790M: Effectiveness of the 80 mg dose. IASLC WCLC 2016 - IASLC 17th World Conference on Lung Cancer, Vienna Austria, Abstract 4403 December 2016 (Poster)
  • Nishan Tchekmedyian, MD, Raja Mudad, MD, MD, Eric Haura, MD, Fernando F. Blanco, PhD, Mark Erlander, PhD, David Berz, MD: Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient responses to EGFR tyrosine kinase inhibitors: A case series. IASLC WCLC 2016 - IASLC 17th World Conference on Lung Cancer, Vienna Austria, December 2016 (Poster)
  • Diana Saravia, Bahar Laderian, Wungki Park, Amrita Desai, Fernando Vargas, Roy Elias, Sean Warsch, Raja Mudad, Chukwuemeka Ikpeazu, Adrian Ishkanian, Lisa Balfe, Mohammad Jahanzeb: Complete Blood Count Parameters as Predictive Factors in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab. IASLC WCLC 2016 - IASLC 17th World Conference on Lung Cancer, Vienna Austria, December 2016 (Poster)
  • Ben Creelan, Justin Gainor, Ramaswamy Govindan, Nancy M. Hardy, John Heymach, Raja Mudad, Karen Reckamp, William Bardwell, Tom Holdich, Lini Pandite, Rafael Amado: “Two Phase I/ II Open Label Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 or MAGE-A10 in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NCT02588612/NCT02592577)”. Clinical Trial in Progress Poster, ASCO Annual meeting Chicago, June 2017 (Poster)
  • Wungki Park, MD1, Gilberto Lopes, MD, Deukwoo Kwon, PhD1, Vaia Florou, MD, Diana Saravia, MD1, Young Kwang Chae, MD, MPH, MBA2, Jessica Warsch, MD, PhD1, Adrian Ishkanian, MD, PhD1, Mohammad Jahanzeb, MD1, MBA1 and Raja Mudad, MD1. “Correlating iSEND and Tumor Mutation Burden (TMB) with Clinical Outcomes of Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients on Nivolumab” IASLC WCLC 2017- IASLC 18th World Conference on Lung Cancer, Yokohama, Japan, October 2017 (Poster)
  • Wungki Park, MD1, Deukwoo Kwon, PhD1, Diana Saravia, MD1, Amrita Desai, MD, MPH1, Jessica Warsch, MD, PhD1, Fernando Vargas, MD1, Mohamed El Dinali, MD1, Roy Elias1, Young Kwang Chae, MD, MPH, MBA,2 Dae Won Kim, MD,3 BMSean Warsch, MD1, Adrian Ishkanian, MD, PhD1, Chukwuemeka Ikpeazu, MD, PhD1, Raja Mudad, MD1, Gilberto Lopes, MD, MBA1, and Mohammad Jahanzeb, MD1. “Developing a Clinical Outcome Model for Advanced Non-Small Cell Lung Cancer Patients Receiving Nivolumab” IASLC WCLC 2017- IASLC 18th World Conference on Lung Cancer, Yokohama, Japan, October 2017 (Poster)
  • Wungki Park, MD, Deukwoo Kwon, PhD, Amrita Desai, MD, MPH, Vaia Florou, MD, Diana Saravia, MD, Jessica Warsch, MD, PhD, Young Kwang Chae, MD, MPH, MBA, Adrian Ishkanian, MD, PhD, Mohammad Jahanzeb, MD, Raja Mudad, MD, and Gilberto Lopes, MD, MBA. “iSEND may predict clinical outcomes for advanced non-small cell lung cancer (aNSCLC) patients treated with check point inhibitors (CPIs) but not with chemotherapy (CHEMO) or targeted kinase inhibitors (TKIs)” IASLC WCLC 2017- IASLC 18th World Conference on Lung Cancer, Yokohama, Japan, October 2017 (Poster)
  • David S Hong, John Heymach, George R. Blumenschein, Vincent Lam, Ben Creelan, Penelope Bradbury, Marcus Butler, Justin Gainor, Ramiswamy Govindan, Melissa Johnson, Raja Mudad, Ryan J. Sullivan, Francine Brophy, Natalie Hyland, Trupti Trivedi, Karen Chagin, Tom Holdich, Elliot Norry, Rafael Amado. Initial Safety Assessment of MAGE-A10 Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells in Two Clinical Trials. ASCO 2018 Chicago June 2018 (Poster presentation)
  • Wungki Park, MD1, Laura Mezquita, MD, PhD, Naoyuki Okabe, MD, PhD, Deukwoo Kwon, PhD, Diana Saravia, MD, Young Kwang Chae, MD, MPH, MBA, Amrita Desai, MD, MPH, David Planchard, MD, PhD, Caroline Caramella, MD, PhD, Raja Mudad, Mohammad Jahanzeb, MD, Hiroyuki Suzuki, MD, PhD, Benjamin Besse, MD, PhD, MD Gilberto Lopes, MD, MBA. Predicting outcomes of patients with advanced non-small cell lung cancer treated with PD-1/PDL-1 inhibitors: independent validation of the iSEND model. ASCO 2018 Chicago June 2018 (Poster Discussion)
  • Wungki Park, Naoyuki Okabe, Diana Saravia, Deukwoo Kwon, Laura Mezquita, Young Kwang Chae, Raja Mudad, Mohammad Jahanzeb, Benjamin Besse, Hiroyuki Suzuki, Gilberto Lopes. Neutrophil-Lymphocyte-Ratio complements the prediction ability of PD-L1 expression for outcomes in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. ASCO 2018 Chicago June 2018 (Abstract Submission)
  • Diana Saravia, MD, Sarita Agte, Naoyuki Okabe, MD, PhD, Wungki Park, MD, Deukwoo Kwon, PhD, Raja Mudad, MD, Hiroyuki Suzuki, MD, PhD , Young Kwang Chae, MD, MPH, MBA, MD Gilberto Lopes, MD, MBA. Neutrophil-to-lymphocyte ratio complements the prognostic ability of PD-L1 expression for outcomes in patients with advanced non-small cell lung cancer treated with single-agent PD-1/PD-L1 inhibitors. WCLC 2018 Toronto, Canada (Abstract submission)
  • Vincent K Lam, David S Hong, John V Heymach, George R Blumenschein, Marcus Butler, Melissa Johnson, Ben C Creelan, Justin F Gainor, Ramaswamy Govindan, Raja Mudad, Joel Neal, Francine Brophy, Frank Fang, Natalie Hyland, Tom Holdich, Yu Ma, Elliot Norry, Rafael Amado. Safety and Anti-Tumour Effects of MAGE-A10c796TCR T-cells in Two Clinical Trials. ESMO 2018 Munich (Abstract Submission)
  • Karen L. Reckamp, Wallace Akerley, Martin J. Edelman, Balazs Halmos, Kai He, Melissa Johnson, Raja Mudad , Joel W. Neal, Taofeek K. Owonikoko, Jyoti D. Patel, Sandip P. Patel, Jonathan W. Riess, Adrian G. Sacher, Simon Turcotte, Liza C. Villaruz, Marjorie G. Zauderer, Benedetto Farsaci, Aisha Hasan, Roma Patel, Yuehui Wu, Michael Chisamore, Vincent Lam : A phase 1b/2a randomized pilot study to investigate the safety and tolerability of autologous T cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer. AACR April 2019, Georgia World Congress Center, Exhibit Hall B, Poster Section 17
  • Poster Board Number: 19 Permanent Abstract Number: CT225 Atlanta, GA

Papers

  • Mudad R, Kane WH: DDAVP in acquired hemophilia A: Case report and review of the literature. Am J Hematol 43:295-299,1993.
  • Mudad R, Vredenburgh J, Paulson EK, Ross M, Meisenberg B, Hussein A, Peters WP: A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis. Cancer 74:1360-1366,1994.
  • Mudad R, Hussein A, Peters WP: Guillain-Barre syndrome following autologous bone marrow transplantation. Am J Clin Oncol (CCT) 18(2): 167-169, 1995.
  • Mudad R, Rao N, Angelisova P, Horejsi V, Telen MJ: Evidence that CDw108
  • membrane protein bears the JMH blood group antigen. Transfusion 35:566-570,
  • 1995
  • Mudad R, Rao N, Issitt PD, Roy RB, Combs MR, Telen MJ: JMH variants: Serological, clinical and biochemical analysis in two cases. Transfusion 35:925-930, 1995.
  • Mudad R, Telen MJ: Biological Functions of Blood Group Antigens. Current Opinion
  • in Hematology 3:473-479, 1996.
  • Zhang XY, Safah H, Mudad R, Maher E, Krause J, Miller A, Ehrlich M: Frequency of BCL-2/JH translocations in peripheral blood of follicular lymphoma patients. American Journal of Hematology 55:205-207,1997.
  • Mahmood T, Mudad R: A case report of carcinoid syndrome with unknown primary. 
  • Am J Clin Oncol, Aug;22(4): 384-386, 1999.
  • Mahmood T, Mudad R: Pulmonary toxicity secondary to Procarbazine.  Am J Clin Oncol. Apr;25(2):187-188, 2002.
  • Reviewed In: Infectious Diseases Review Series, Issue 2:12-13, 2003 by C.A.T. Bremer, T. Mahmood, R. Mudad.
  • Bremer CA, Lastrapes A, Alper AB, Mudad R: Interferon alpha-induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: A case report and review of the literature. Am J Clin Oncol. Jun; 26(3):262-4, 2003.
  • Mudad R, Ramsey M, Kovitz K, Curiel T, Hartz R, Nedzi LL, Weiner RS, Zakris EL: Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: A dose finding study. Lung Cancer 39(2): 173-177, 2003.
  • Raez LE, Santos ES, Mudad R, Podack ER. Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines. Expert Rev Anticancer Ther. Aug;5(4):635-44, 2005
  • Kahn MJ, Mudad R, Glotzbach JP, Owens DP Jr. Perspectives on the cancer death of a medical student. Am J Hosp Palliat Care. Sep-Oct;22(5):393-6, 2005
  • Tchkemedyian N, Mudad R, Blanco FF, Raymond VM, Garst J, Erlander MG, Haura E and Berz D. Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series. Lung Cancer. 2017 Jun;108:22-28. doi: 10.1016/j.lungcan.2017.02.010. Epub 2017 Feb 20.
  • Mudad R, MD; Patel MB, PharmD; Margunato-Debay S, PharmD, MBA; Lal LS, PharmD, PhD; Garofalo D, MS, MBA: Comparative Effectiveness and Safety of nab-Paclitaxel Plus Carboplatin vs. Gemcitabine Plus Carboplatin in First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer in a U.S. Community Oncology Setting. Lung Cancer (Auckl). 2017 Oct 19;8:179-190. doi: 10.2147/LCTT.S139647. eCollection 2017
  • Fadi Farhat, MD, Alfredo Torres MD, Gilberto de Lima Lopes, MD, Raja Mudad, MD, Chukwuemeka Ikpeazu, MD, Simon Abi Aad, MD: The Concept of Biosimilars: from Characterization to Evolution – A Narrative Review. Oncologist. 2018 Mar;23(3):346-352. doi: 10.1634/theoncologist.2017-0126. Epub 2017 Dec 28. Review.PMID: 29284760
  • Wungki Park, MD, Deukwoo Kwon, PhD, Diana Saravia, MD, Amrita Desai, MD, MPH, Fernando Vargas, MD, Mohamed El Dinali, MD, Jessica Warsch MD, PhD, Roy Elias,ƿ Young Kwang Chae, MD, MPH, MBA, Dae Won Kim, MD, Sean Warsch, MD, Adrian Ishkanian, MD, PhD, Chukwuemeka Ikpeazu, MD, PhD, MBA, Raja Mudad, MD, Gilberto Lopes, MD, MBA, and Mohammad Jahanzeb, MD. “Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab.” Clin Lung Cancer. 2018 May;19(3):280-288.e4. doi: 10.1016/j.cllc.2017.12.007. Epub 2017 Dec 21.PMID: 29336998
  • Sandra D. Algaze, MD; Wungki Park, MD; Thomas J. Harrington, MD; Raja Mudad, MD. “Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin”. BMJ Case Rep. 2018 Mar 9;2018. pii: bcr-2017-221801. doi: 10.1136/bcr-2017-221801. PMID: 29523604
  • Muhammad Husnain; Wungki Park; Juan Carlos Ramos; Thomas E. Johnson; Joseph Chan; Arvind Dasari; Raja Mudad; Peter J Hosein. Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection. Journal for Immunotherapy of Cancer, 2018 6:66, Published: 9 July 2018
  • Mohamad Masri, Martine McManus, Raja Mudad. Treatment of Advanced Non-small cell lung cancer in the Era of Targeted Therapy. Curr Pulmonol Rep (2018) 7: 79. https://doi.org/10.1007/s13665-018-0204-5
  • Sofia Palacio, Luciola Pontes, Junaid Arshad, Robert Ali, Tony Piha, Carlos Eduardo Bacchi, Edna, Prado, Raja Mudad, Gilberto Lopes. EGFR mutation testing: changing patterns of molecular testing in Brazil. Oncologist. 2018 Nov 16.
  • Robert Ali, Junaid Arshad, Sofia Palacio, Raja Mudad. Brigatinib for ALK+ metastatic non-small cell lung cancer: design, development and place in therapy. Drug Design, Development and Therapy, 8 February 2019 Volume 2019:13 Pages 569—580
  • Wassim Mchayleh,, Ellie Kamarjian, Gretel Terrero, Raja Mudad.  The role of immunotherapy in the treatment of small cell lung cancer. Submitted
Raja Mudad, M.D. FACP - Thoracic Medical Oncologist
  • 3585 NE 207th Street
    Aventura, FL 33190

    Tel:

  • 21020 State Rd 7, Suite 200 B-C
    Boca Raton, FL 33428

  • 3585 NE 207th Street, Suite C6-7
    Aventura, FL 33190